474 related articles for article (PubMed ID: 33972572)
1. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model.
Saraiva SM; Gutiérrez-Lovera C; Martínez-Val J; Lores S; Bouzo BL; Díez-Villares S; Alijas S; Pensado-López A; Vázquez-Ríos AJ; Sánchez L; de la Fuente M
Sci Rep; 2021 May; 11(1):9873. PubMed ID: 33972572
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of edelfosine lipid nanoparticles in breast cancer cells.
Aznar MÁ; Lasa-Saracíbar B; Estella-Hermoso de Mendoza A; Blanco-Prieto MJ
Int J Pharm; 2013 Oct; 454(2):720-6. PubMed ID: 23643510
[TBL] [Abstract][Full Text] [Related]
3. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
4. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S
Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma.
Estella-Hermoso de Mendoza A; Préat V; Mollinedo F; Blanco-Prieto MJ
J Control Release; 2011 Dec; 156(3):421-6. PubMed ID: 21821074
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
7. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
8. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
Guo Y; Fan Y; Pei X
Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
[TBL] [Abstract][Full Text] [Related]
9. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
11. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
14. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
Khurana RK; Kumar R; Gaspar BL; Welsby G; Welsby P; Kesharwani P; Katare OP; Singh KK; Singh B
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():645-658. PubMed ID: 30033299
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
16. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
18. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
19. A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature.
El-Sahli S; Hua K; Sulaiman A; Chambers J; Li L; Farah E; McGarry S; Liu D; Zheng P; Lee SH; Cui J; Ekker M; Côté M; Alain T; Li X; D'Costa VM; Wang L; Gadde S
Cell Death Dis; 2021 Jan; 12(1):8. PubMed ID: 33414428
[TBL] [Abstract][Full Text] [Related]
20. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
